Oxytocin receptor–beta-2 adrenergic receptor heterodimer (OTR–ADRB2 heterodimer)

The Oxytocin receptor–beta-2 adrenergic receptor (OTR–ADRB2) heterodimer is a specific G protein-coupled receptor (GPCR) complex formed by the physical interaction of the oxytocin receptor (OXTR) and the beta-2 adrenoceptor (ADRB2) (PMID: 25608234). This heterodimer is primarily studied in the context of the human myometrium, where it regulates the transition between uterine quiescence and labor (PubMed: 30120123). The formation of the OTR–ADRB2 complex allows for functional cross-talk, where the activation of the Gs-coupled ADRB2 can allosterically modulate or inhibit the Gq-mediated signaling of the OTR, thereby promoting smooth muscle relaxation (PMID: 25608234). This interaction is significant for the efficacy of tocolytic drugs like terbutaline, which may rely on this heteromerization to counteract oxytocin-induced contractions during preterm labor (Source: Journal of Biological Chemistry). Furthermore, the expression and dimerization state of these receptors are known to change during different stages of pregnancy, making the heterodimer a potential target for more precise therapeutic interventions in obstetric complications (Source: Frontiers in Endocrinology).

Other names

OXTR-ADRB2 heteromerOxytocin receptor-beta-2 adrenoceptor complexOTR-B2AR heterodimerOXTR-ADRB2 heterodimeric complex

The heterodimer facilitates functional cross-talk where the activation of the beta-2 adrenergic receptor (Gs-coupled) can allosterically inhibit the signaling of the oxytocin receptor (Gq-coupled), leading to enhanced myometrial relaxation and inhibition of contractions.